$23.45 -0.05 (-0.21%)
11/20/2009 4:00 PM

Par Pharmaceutical Companies, Inc. (PRX)

CAPS Rating: 3 out of 5

The Company, through its subsidiary Par Pharmaceutical, Inc., is engaged in the development, manufacture and distribution of generic pharmaceuticals and branded pharmaceuticals in the United States.

Current Price $23.45 Mkt Cap $816.51M
Open $23.41 P/E Ratio 20.22
Prev. Close $23.45 Div. (Yield) N/A (N/A)
Daily Range $23.23 - $23.52 Volume 294,022
52-Wk Range $7.91 - $24.23 Avg. Daily Vol. 621,000

PRX News and Commentary

Caps

How do you think PRX will perform vs the S&P 500?

Add Stock to Watchlist

All Members

150 Outperform
22 Underperform
 

All-Star Members

41 Outperform
5 Underperform
 

Wall Street

5 Outperform
2 Underperform
 

Top PRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

00746angel (< 20)
Submitted February 19, 2007

shipping out new approved drugs
as fast as they can produce them
pipe lines need to be filled
also esclusive rights for six months

0 Comments | Reply | Report this Post

dustbusterz (< 20)
Submitted August 24, 2007

wow - take a look at the stats on this company. right at the moment, it appears to be beating the market as far as stock appreciation goes, but this baffles me . they have a net loss on growth,net loss on profit margins,operating margins are slim to… More

0 Comments | Reply | Report this Post
PRX VS S&P 500 (SPY)

Fools bullish on PRX are also bullish on:

Fools bearish on PRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about PRX.

Recs

0
Member Avatar manucastle (68.11) Submitted: 11/19/2009 7:16:35 AM : Outperform Start Price: $22.31 PRX Score: +5.50

Update for latest results for PRX which I own :-

http://finance.yahoo.com/q?s=prx&.yficrumb=yIQAwlz5SoW

Industry: biotechnology & drugs
EPS = 1.05
EPS EST 1yr = 2.363 2yr = 1.475
EPS EST Q1 = 0.489 Q2 = 0.407
PE = 21.7 Industry 14.4
PB = 1.59 Industry 2.7
PS = 0.72 Industry 3.5
P/CF = 21.7 industry 12.5
P/FCF = 8.9 Industry 13.5
Yield 0.0 Industry 0.0
Gross profit margin = 27.5 Industry 51.0
Operating margin = 5.1 Industry -41.2
Net Profit Margin = 3.2 Industry -41.4
ROA = 4.4 Industry -52.8
ROE = 7.7 Industry -12.9
Insider ownership = 2.4
Greenblatt ROC = 22.99
Greenblatt Earnings Yield = 8.04
PosFCF generic % free cash flow yield 11.26%***
LT debt less than Gross Income = Pass
Passes 12 of 17 of Mike Klein's metrics
MaxPrice = 92.85 Discount 75%**
Metrics from qtr ending 10/03/2009
Caps rank 3
http://caps.fool.com/Ticker/PRX.aspx
MC score 235

All good enough for my money. I only suggest stocks that I own !

(See posts 388/584/665/760/1051/1807/2213/3546/3755/4046/4208/4225/4345/4573/4818/5241/5242/5310/5461/5579/
5169/7651 on 'Investment Analysis Clubs / Dynamic Value Investing ' board for extra due diligence applied ). **MaxPrice is a generic version of Mike Klein's Maxprice and ROC and Earnings yields are generic versions of Greenblatt's metrics. *** PosFCF generic % free cash flow yield taken from AAII and posts 5248 and 5253

See 'Investment Analysis Clubs / Dynamic Value Investing' board and my CAPS profile for further excellent companies selling at a discount to Maxprice with excellent current metrics. CAPS only shows my selections over 100Mill (unfortunately due to restricted lower market cap applied by MF CAPS).

As stated on the 'Investment Analysis Clubs /Dynamic Value Investing' board my aim is to obtain up to 50% returns p.a. as Buffett stated he could obtain (3 times) recently. A very difficult task but you can follow along with my buys and sells on my CAPS page, where I put my money where my mouth is . If I perform well I hope you can benefit. If not , feel free to ignore my comments. CAPS allows each and everyone of us to be clinically judged on our stock picking abilities over the LONG TERM.

Please always do your own due diligence before investing.

Manucastle :o)

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar IGUESS2 (< 20) Submitted: 11/17/2009 10:43:24 PM : Outperform Start Price: $23.89 PRX Score: -0.20

Par Pharmaceutical Companies is a holding company in the business of developing, manufacturing and distributing generic and branded drugs in the U.S. Par sports a D/E of .15, cash per share $6.04. cash flow $2.18 and a short interest of 3.52%. Earnings surged each of the last three quarters and pulverized estimates.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar IBDvalueinvestin (96.34) Submitted: 11/6/2009 11:31:16 AM : Outperform Start Price: $23.50 PRX Score: -3.20

PRX looking to get approvals on an additional $6.5B worth of drugs.

PRX Total revenue nearly doubled to $294.8 million

Analysts on average expected earnings of 49 cents a share on revenue of $290.4 million, according to Thomson Reuters I/B/E/S.

PRX said it currently has about 27 abbreviated new drug applications pending with the U.S. health regulators, 13 of which the company believes have first-to-file or first-to-market opportunities with a brand value of about $6.5 billion.

Report this Post 0 Comments | Reply | Permalink
View All 25 Pitches »

Leaderboard

Find the members with the highest scoring picks in PRX.

Score Leader

TrackCarisandCo

TrackCarisandCo (76.69) Score: +105.31

The Score Leader is the member with the highest score across all their picks in PRX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
BBQPrinceofPork 25.31 7/7/2006 Outperform 5Y $13.03 +79.97% -8.49% +88.46
TheHague 77.11 4/9/2009 Outperform NS $10.87 +115.73% +30.60% +85.13 1 Comment
Superman2bad4u 73.61 4/29/2009 Outperform 5Y $11.19 +109.56% +26.36% +83.20 1 Comment
ellistea1024 < 20 3/23/2009 Outperform NS $10.64 +120.39% +40.43% +79.97
wepencryption < 20 3/23/2009 Outperform NS $10.64 +120.39% +40.43% +79.97
stevez24 80.22 3/26/2009 Outperform 3M $11.05 +112.22% +34.70% +77.52 1 Comment
runtheworld 93.91 4/20/2009 Outperform 1Y $11.35 +106.61% +29.26% +77.35
SSPX1 83.88 5/7/2009 Outperform NS $11.99 +95.58% +18.88% +76.70
SSPX7 20.73 5/8/2009 Outperform NS $11.92 +96.73% +20.15% +76.58
TMFEldrehad 99.99 7/7/2006 7/27/2009 Outperform 3Y $14.00 +67.50% -8.22% +75.72
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackBarclaysCap 86.21 10/16/2009 Outperform NS $22.98 +2.05% +0.60% +1.45
TrackCarisandCo 76.69 11/10/2008 Outperform NS $10.45 +124.40% +19.09% +105.31
TrackNeedham < 20 9/25/2008 Outperform NS $13.00 +80.38% -6.05% +86.44
TrackJPMorgan 73.67 3/4/2008 Underperform NS $18.60 +26.08% -13.75% -39.83
TrackFBRCapitalM 73.72 10/1/2007 Underperform NS $17.67 +8.49% -12.80% -21.29 2/8/2008 @ $19.17
TrackSoros 24.12 9/30/2007 Outperform NS $18.56 +26.35% -24.86% +51.20 1 Comment
TrackLeerinkSwan 83.04 5/21/2007 Outperform NS $28.78 -18.52% -24.17% +5.65
TrackJimCramer 36.31 2/5/2007 Underperform 3W $26.89 -12.79% -19.81% -7.02
TrackLehmanBros 66.51 11/22/2006 Outperform NS $19.73 +4.05% +5.45% -1.39 12/13/2007 @ $20.53

Featured Broker Partners